1st qtr sales, US-up 11% STJ stock rocking today! I believe STJ is poised to take off in the NM market! NMD Leadership and the acquisition of Spinal Modulation and promising Burst technology is the envy of MDT and BSX! BUY!
NMD UP!
- Thread starter Anonymous
- Start date
-
- Tags
- None
oh no, not another whiner? Man up, the NSM's over and its time to get to work. You are in sales aren't you? Well then, start selling and stop complaining.
I have to agree. You are either making a joke to see what 'news' happened at our NSM or you are just absolutely stupid.
Let me summarize....no new products...not even an F'n trial system are going to be approved for 12 mos.
If you truly are that dumb, then 'thank you'. That is one less person looking for a job while the rest of us are interviewing.
I'm glad I didn't meet you in Chicago because I would have laughed out loud in your face...Corky!
Let me summarize....no new products...not even an F'n trial system are going to be approved for 12 mos.
If you truly are that dumb, then 'thank you'. That is one less person looking for a job while the rest of us are interviewing.
I'm glad I didn't meet you in Chicago because I would have laughed out loud in your face...Corky!
Can't sell? grow a pair, you're in the wrong business pal. Get a job at Whole Foods, I hear they're looking for guys like you in the fish dept, Flipper!
Great comment, Corky as in from Life Goes On??
KB is turning this thing around, I have no doubts. Give him some time and he'll be making us all rich! He understands the business better than anyone and will take care of you if you do your job. He treat's people well that produce and don't threaten him. Keep your mouth shut and you'll be fine
Looking average expected territory manager earnings. Base, total comp, auto. Not looking to get flammed here with the common "stay away" or "run". Real answers would be helpful, my research shows a lot of fluctuation - so looing for an accurate 2015 projection.
Quality of life? Is the patient-call schedule really as demanding as everyone harps about? How difficult is a conversion from medtronic or boston?
Fairly simple. Both systems have a lot of problems for patients
Seriously?!? There is a reason SJM is winning the bronze medal in this three pony market (for now) and it's not because the company doesn't spend enough $$ on KOLs.
To resolve issues, please just begin referring all patients to Nevro. Game over Mudtronic, St Junk and Butthole Scientific. We have the science, the team, the connections and the network to make this game very short lived in favor of Senza!!! Let the games begin
St. Jude Medical ($STJ) expects that gains in the neuromodulation market will undergird an improved revenue growth rate over the next few years. Key to that strategy is the Axium Neurostimulator System to treat chronic lower limb pain. In January, the company submitted to the FDA for a PMA approval for the device. Now it's released positive superiority data for Axium as compared to a traditional spinal cord stimulation (SCS) device from competitor Medtronic ($MDT).
This positive data was the trigger for St. Jude to exercise its option to buy Spinal Modulation, or SMI, for up to $175 million up front with additional undisclosed payments upon FDA approval of the Axium system and with the achievement of undisclosed revenue targets. The deal closed in May and the option stemmed from a 2013 deal that included St. Jude's distribution of the device in Europe under a 2011 CE mark.
In the data from the ACCURATE study for Axium, the system was found to achieve greater significant pain relief and treatment success versus the Medtronic SCS device--81.2% versus 55.7%. The study involved 152 patients at 22 U.S. centers. These included patients suffering from chronic lower limb pain associated with complex regional pain syndrome or peripheral causalgia, known more simply as nerve damage.
This study completed in December. St. Jude chairman, President and CEO Daniel Starks commented in April on the study, "The successful completion of the IDE study prompted us to exercise our option to acquire SMI. The IDE study compared to safety and efficacy of the Axium System with Medtronic's RestoreULTRA and RestoreSensor System for the indication of intractable pain of the lower limbs," he said. "The SMI study met its primary composite endpoints both for non-inferiority and for superiority over the Medtronic products."
Patients in the Axium group were significantly less likely to report feeling stimulation outside the area of pain. But both groups reported similar experiences with the intensity of paresthesia. This could prove an advantage for the Senza chronic pain implant from competitor Nevro ($NVRO) that was recently approved by the FDA and is designed specifically to eliminate the unpleasant side effect of paresthesia.
St. Jude expects the SMI acquisition will be accretive to adjusted EPS starting in 2016, particularly after an anticipated FDA approval for Axium.
The Axium system stimulates the dorsal root ganglion (DRG), which contain primary sensory neurons that transmit pain signals to the brain. St. Jude is the only devicemaker to offer a DRG stimulation device to treat chronic pain, according to the company.
"Data from the ACCURATE Study are exciting because they demonstrate that DRG stimulation can offer meaningful improvement over traditional spinal cord stimulation for patients suffering from chronic pain conditions that have historically been challenging to treat," said St. Jude CMO Dr. Mark Carlson. "We look forward to continuing to develop DRG stimulation therapy to expand availability for patients currently underserved by traditional chronic pain therapy options."
This positive data was the trigger for St. Jude to exercise its option to buy Spinal Modulation, or SMI, for up to $175 million up front with additional undisclosed payments upon FDA approval of the Axium system and with the achievement of undisclosed revenue targets. The deal closed in May and the option stemmed from a 2013 deal that included St. Jude's distribution of the device in Europe under a 2011 CE mark.
In the data from the ACCURATE study for Axium, the system was found to achieve greater significant pain relief and treatment success versus the Medtronic SCS device--81.2% versus 55.7%. The study involved 152 patients at 22 U.S. centers. These included patients suffering from chronic lower limb pain associated with complex regional pain syndrome or peripheral causalgia, known more simply as nerve damage.
This study completed in December. St. Jude chairman, President and CEO Daniel Starks commented in April on the study, "The successful completion of the IDE study prompted us to exercise our option to acquire SMI. The IDE study compared to safety and efficacy of the Axium System with Medtronic's RestoreULTRA and RestoreSensor System for the indication of intractable pain of the lower limbs," he said. "The SMI study met its primary composite endpoints both for non-inferiority and for superiority over the Medtronic products."
Patients in the Axium group were significantly less likely to report feeling stimulation outside the area of pain. But both groups reported similar experiences with the intensity of paresthesia. This could prove an advantage for the Senza chronic pain implant from competitor Nevro ($NVRO) that was recently approved by the FDA and is designed specifically to eliminate the unpleasant side effect of paresthesia.
St. Jude expects the SMI acquisition will be accretive to adjusted EPS starting in 2016, particularly after an anticipated FDA approval for Axium.
The Axium system stimulates the dorsal root ganglion (DRG), which contain primary sensory neurons that transmit pain signals to the brain. St. Jude is the only devicemaker to offer a DRG stimulation device to treat chronic pain, according to the company.
"Data from the ACCURATE Study are exciting because they demonstrate that DRG stimulation can offer meaningful improvement over traditional spinal cord stimulation for patients suffering from chronic pain conditions that have historically been challenging to treat," said St. Jude CMO Dr. Mark Carlson. "We look forward to continuing to develop DRG stimulation therapy to expand availability for patients currently underserved by traditional chronic pain therapy options."
To resolve issues, please just begin referring all patients to Nevro. Game over Mudtronic, St Junk and Butthole Scientific. We have the science, the team, the connections and the network to make this game very short lived in favor of Senza!!! Let the games begin
Curious to know what the recharge burden is on the Senza. Early rumors were that patients were charging daily. Is that accurate??
Just had a recruiter call me. Comp sounded exceptional, I'm curious if the numbers he's talking are accurate. 80K base, 10% from dollar ONE. I'd be curious to see of these number are accurate. Thanks in advance!